Clinical Trial Goal
To find out:
- The highest dose of mezigdomide that's safe to give with teclistamab
- If the combination of mezigdomide and teclistamab is safe and works well to treat mutliple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Do not have primary amyloidosis
- Have not been treated with mezigdomide
- Have not been treated with a bispecific antibody that targets BCMA in the last 2 months. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not had an autologous (your own cells) BMT in the last 2 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Mezigdomide is a cereblon E3 ligase modulator that doctor's think may work better at finding and killing myeloma cells.
Teclistamab is a bispecific antibody that targets BCMA and CD3 on certain cells.
You’ll get:
Teclistamab is a bispecific antibody that targets BCMA and CD3 on certain cells.
You’ll get:
- Mezigdomide – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Teclistamab – The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved mezigdomide.
Contacts
Malin Hultcrantz, MD, PhD, 646-608-3714, hultcram@mskcc.org
Ross Firestone, MD, PhD, MS, 646-608-2014
Locations
Sponsors
collaborator: Bristol-Myers Squibb, collaborator: Johnson & Johnson, lead: Memorial Sloan Kettering Cancer Center
